AI Sepsis Risk Tool Reaches Distribution Deal

Image credit: Prenosis

US-based medtech, Prenosis has this month announced a deal with global healthcare giant, Roche to distribute the Sepsis ImmunoScore – a unique artificial intelligence-driven, machine learning software as a medical device (AI SaMD) supporting a swift diagnosis of sepsis and likelihood of poor outcomes in patients.

The first-ever AI diagnostic tool for sepsis with De Novo approval from the US Food and Drug Administration (FDA), the Sepsis ImmunoScore uses biomarkers, clinical data and AI to predict a patient’s chances of having or developing sepsis within 24 hours of assessment.

It will be available to clinicians on Roche’s navify Algorithm Suite online portal.

“Including the Sepsis ImmunoScore in Roche’s navify Algorithm Suite is a great step forward for the Sepsis ImmunoScore,” said Prenosis Co-Founder and CEO, Bobby Reddy Jr in a statement.

“With the extensive market reach of Roche Diagnostics and ethical standards for AI-driven solutions, more hospitals and healthcare providers can take advantage of ImmunoScore, and its clinical utility in the fight against sepsis, in a responsible way.”

Prenosis’ dataset behind its AI technology combines biomarker and clinical information from over 25,000 patients, and is claimed by company to be the largest in the world for fast-moving immune response in acute care settings.

Sepsis is a serious medical condition which accounts for an estimated 8,000 deaths in Australia alone each year.

Refer to the full press statement for more information.